On July 26, 2024, Windtree Therapeutics Entered Into A Securities Purchase Agreement With A Buyer For A Private Placement Of 1,250 Series C Convertible Preferred Shares And Warrants For Up To 267,380 Shares Of Common Stock, For About $1M In Gross Proceeds
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics has entered into a securities purchase agreement for a private placement of 1,250 Series C Convertible Preferred Shares and warrants for up to 267,380 shares of common stock, generating approximately $1 million in gross proceeds.
July 29, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Windtree Therapeutics has secured a private placement deal involving Series C Convertible Preferred Shares and warrants, raising $1 million in gross proceeds. This move could provide the company with necessary capital for its operations and growth.
The private placement will provide Windtree Therapeutics with additional capital, which could be used for operational needs or growth initiatives. This is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100